Yuan Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yuan Liu has a total of 398 co-authors. Here are the top co-authors by number of shared publications:
- Gregory B. Lesinski
Emory University
55 shared publications - Chrystal M. Paulos
Winship Cancer Institute, Emory University
29 shared publications - Edmund K. Waller
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA
26 shared publications - Hanwen Zhang
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, USA
25 shared publications - Jian-Ming Li
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia. 1
25 shared publications - Sruthi Ravindranathan
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia. 1
25 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Data from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
Adoptive T-cell transfer (ACT) therapy offers curative potential for some patients with cancer. Toll-like receptor (TLR) agonists improve the efficacy of ACT therapy, and elucidating the underlying mechanism of potency could help determine the best way to maximize the benefits of TLR agonists. In this study, we identified an innate–adaptive circuit in which TLR9-activated B cells augment CD8+ T-cell fitness and antitumor activity through CD2-dependent costimulation. Among multiple TLR agonists tested, class B CpG uniquely programmed murine and human CD8+ T cells for superior effector differentiation, metabolic fitness, and antitumor control. Disruption of CD2 signaling blunted the benefits of TLR9 agonism, including impaired glycolytic capacity and reduced tumor control. Independently, blocking other costimulatory molecules, such as CD86, CD80, CD28, or inducible T-cell costimulator (ICOS), did not impair the antitumor activity of CpG-conditioned T cells. Gain-of-function experiments revealed that CD2 stimulation recapitulated the effect of TLR9 agonism, bolstering the effector function of tumor-infiltrating lymphocytes and chimeric antigen receptor (CAR) T cells. Consistent with these findings, elevated CD2 expression in human tumors correlated with improved overall survival across multiple patient cohorts with cancer, underscoring the clinical importance of this signaling cue. Together, these data uncover a noncanonical B-cell–CD2 costimulation axis through which TLR9 agonists potentiate ACT, revealing a targetable pathway to overcome resistance to cell therapy in solid tumors. Significance:B cells activated with TLR9 agonist cross-talk with CD8+ T cells via CD2, which enhances their fitness, cytotoxic function, and antitumor activity against solid tumors.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
Adoptive T-cell transfer (ACT) therapy offers curative potential for some patients with cancer. Toll-like receptor (TLR) agonists improve the efficacy of ACT therapy, and elucidating the underlying mechanism of potency could help determine the best way to maximize the benefits of TLR agonists. In this study, we identified an innate–adaptive circuit in which TLR9-activated B cells augment CD8+ T-cell fitness and antitumor activity through CD2-dependent costimulation. Among multiple TLR agonists tested, class B CpG uniquely programmed murine and human CD8+ T cells for superior effector differentiation, metabolic fitness, and antitumor control. Disruption of CD2 signaling blunted the benefits of TLR9 agonism, including impaired glycolytic capacity and reduced tumor control. Independently, blocking other costimulatory molecules, such as CD86, CD80, CD28, or inducible T-cell costimulator (ICOS), did not impair the antitumor activity of CpG-conditioned T cells. Gain-of-function experiments revealed that CD2 stimulation recapitulated the effect of TLR9 agonism, bolstering the effector function of tumor-infiltrating lymphocytes and chimeric antigen receptor (CAR) T cells. Consistent with these findings, elevated CD2 expression in human tumors correlated with improved overall survival across multiple patient cohorts with cancer, underscoring the clinical importance of this signaling cue. Together, these data uncover a noncanonical B-cell–CD2 costimulation axis through which TLR9 agonists potentiate ACT, revealing a targetable pathway to overcome resistance to cell therapy in solid tumors. Significance:B cells activated with TLR9 agonist cross-talk with CD8+ T cells via CD2, which enhances their fitness, cytotoxic function, and antitumor activity against solid tumors.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
CpG conditioning by distinct CpG classes on pmel-1 CD8 increases T cell activation and cytokine production
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
CpG conditioning by distinct CpG classes on pmel-1 CD8 increases T cell activation and cytokine production
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
CD28 or Icos blocking does not impair CpG conditioned CD8 T cells
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
CD28 or Icos blocking does not impair CpG conditioned CD8 T cells
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
CD2 signaling is required for TLR9 driven B cell differentiation
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
CD2 signaling is required for TLR9 driven B cell differentiation
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
Metabolic profiling of B cells and CD8 T cells following CpG conditioning and CD2 blockade
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
Metabolic profiling of B cells and CD8 T cells following CpG conditioning and CD2 blockade
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
Flow cytometry and blocking antibody list
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
Flow cytometry and blocking antibody list
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
TLR9-activated B cell interactions with human CD8 T cells may limit their exhaustion
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
TLR9-activated B cell interactions with human CD8 T cells may limit their exhaustion
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
CD2 and CD58 expression is increased in intratumoral human B and T cells
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
CD2 and CD58 expression is increased in intratumoral human B and T cells
- 26 July 2026
- Published by Wiley in Journal of Surgical Oncology
- Vol. 134 (5) , 720-729
Impact of Adjuvant Chemotherapy on Overall Survival in Early‐Onset Stage II‐III Mucinous Adenocarcinoma of The Colon: A Propensity‐Based Analysis
Background: Incidence of early‐onset colon cancer is rising. Younger patients often present with advanced disease and distinct molecular profiles. Mucinous adenocarcinoma (MAC) represents a biologically unique subtype that may demonstrate limited responsiveness to adjuvant chemotherapy (AC). This study evaluated association between AC and overall survival (OS) in patients with early‐onset stage II and III MAC. Methods: Patients aged < 50 years diagnosed with stage II‐III MAC were identified from NCDB (2006‐2020). Stage II was categorized as high‐ or low‐risk, with high‐risk defined by presence of ≥ 1 of: < 12 lymph nodes retrieved, lymphovascular/perineural invasion, poor differentiation, or pT4 disease. Stabilized inverse probability of treatment weighting, Kaplan‐Meier analysis, and multivariable Cox regression were performed to assess the association between AC and OS. Results: Among 3333 patients, 42.9% were stage II and 57.1% stage III. AC was administered to 70.1% of patients, including 41.3% with stage II and 91.7% with stage III disease. AC was not associated with improved OS in either high‐risk or low‐risk stage II subgroups but was significantly associated with improved OS in stage III disease (HR 0.71, 95% CI 0.54–0.93). Conclusion: AC was associated with improved survival in stage III but not stage II early‐onset MAC, including those with high‐risk features.
- 26 July 2026
- Published by Wiley in Journal of Surgical Oncology
- Vol. 134 (5) , 720-729
Impact of Adjuvant Chemotherapy on Overall Survival in Early‐Onset Stage II‐III Mucinous Adenocarcinoma of The Colon: A Propensity‐Based Analysis
Background: Incidence of early‐onset colon cancer is rising. Younger patients often present with advanced disease and distinct molecular profiles. Mucinous adenocarcinoma (MAC) represents a biologically unique subtype that may demonstrate limited responsiveness to adjuvant chemotherapy (AC). This study evaluated association between AC and overall survival (OS) in patients with early‐onset stage II and III MAC. Methods: Patients aged < 50 years diagnosed with stage II‐III MAC were identified from NCDB (2006‐2020). Stage II was categorized as high‐ or low‐risk, with high‐risk defined by presence of ≥ 1 of: < 12 lymph nodes retrieved, lymphovascular/perineural invasion, poor differentiation, or pT4 disease. Stabilized inverse probability of treatment weighting, Kaplan‐Meier analysis, and multivariable Cox regression were performed to assess the association between AC and OS. Results: Among 3333 patients, 42.9% were stage II and 57.1% stage III. AC was administered to 70.1% of patients, including 41.3% with stage II and 91.7% with stage III disease. AC was not associated with improved OS in either high‐risk or low‐risk stage II subgroups but was significantly associated with improved OS in stage III disease (HR 0.71, 95% CI 0.54–0.93). Conclusion: AC was associated with improved survival in stage III but not stage II early‐onset MAC, including those with high‐risk features.
- Open Access
- 8 July 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (8)
Novel risk scoring system for patients with metastatic castration-resistant prostate cancer treated with lutetium-177–PSMA-617
Purpose: Lutetium-177(177Lu)–PSMA-617 improves survival for patients with metastatic castration-resistant prostate cancer, but outcomes are heterogeneous and standardized risk stratification tools are lacking. We developed a novel risk stratification tool for patients treated with 177Lu–PSMA-617. Methods: We conducted a retrospective analysis of 163 patients at Emory Winship Cancer Institute. Four prognostic models using Cox proportional hazards models were constructed using best-subset variable selection and integrated into a composite model. Results: Among the 163 patients (52% White, 44% Black; 80% previous taxane use) body mass index decline during treatment was associated with shorter progression-free survival (PFS) and overall survival (OS) (HR = 1.75, P = .03; HR = 2.35, P = .031). Higher subcutaneous adipose tissue index (SATI)/skeletal muscle index (SMI) was independently associated with improved OS (HR = 0.5, P = .019), whereas higher visceral adipose tissue index (VATI)/SATI was independently associated with worse OS (HR = 2.62, P = .005). A body composition-based prognostic score identified VATI/SATI, SMI, and total adiposity as the strongest OS predictors (C = 0.629). The composite score incorporating inflammatory biomarkers and body composition demonstrated good discrimination (C-index = 0.732) and effectively stratified patients by PFS and OS. For PFS, relative risks across increasing risk quartiles were 0.34, 0.40, and 0.62 in compared with the highest risk quartile (P = .034). For OS, corresponding hazard ratios were 0.15, 0.19, and 0.54 (P = .003). Conclusions: A risk score incorporating body composition and inflammatory biomarkers demonstrates prognostic value for patients treated with 177Lu–PSMA-617.
- 8 July 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (8)
Open AccessNovel risk scoring system for patients with metastatic castration-resistant prostate cancer treated with lutetium-177–PSMA-617
Purpose: Lutetium-177(177Lu)–PSMA-617 improves survival for patients with metastatic castration-resistant prostate cancer, but outcomes are heterogeneous and standardized risk stratification tools are lacking. We developed a novel risk stratification tool for patients treated with 177Lu–PSMA-617. Methods: We conducted a retrospective analysis of 163 patients at Emory Winship Cancer Institute. Four prognostic models using Cox proportional hazards models were constructed using best-subset variable selection and integrated into a composite model. Results: Among the 163 patients (52% White, 44% Black; 80% previous taxane use) body mass index decline during treatment was associated with shorter progression-free survival (PFS) and overall survival (OS) (HR = 1.75, P = .03; HR = 2.35, P = .031). Higher subcutaneous adipose tissue index (SATI)/skeletal muscle index (SMI) was independently associated with improved OS (HR = 0.5, P = .019), whereas higher visceral adipose tissue index (VATI)/SATI was independently associated with worse OS (HR = 2.62, P = .005). A body composition-based prognostic score identified VATI/SATI, SMI, and total adiposity as the strongest OS predictors (C = 0.629). The composite score incorporating inflammatory biomarkers and body composition demonstrated good discrimination (C-index = 0.732) and effectively stratified patients by PFS and OS. For PFS, relative risks across increasing risk quartiles were 0.34, 0.40, and 0.62 in compared with the highest risk quartile (P = .034). For OS, corresponding hazard ratios were 0.15, 0.19, and 0.54 (P = .003). Conclusions: A risk score incorporating body composition and inflammatory biomarkers demonstrates prognostic value for patients treated with 177Lu–PSMA-617.